-
BioLineRx Licenses Multiple Myeloma Drug Motixafortide to Guangzhou Gloria Biosciences
•
Israel’s BioLineRx has entered into a licensing agreement with Guangzhou Gloria Biosciences Co., Ltd., based in China, focusing on the development of BioLineRx’s multiple myeloma drug, motixafortide. This strategic partnership grants Gloria exclusive rights to develop motixafortide across all indications throughout Asia. As part of the agreement, Gloria is making…
-
Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion
•
Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY) increase in global sales, reaching USD 6.5 billion. This growth comes despite a 3% decrease in net selling price, primarily fueled by an impressive 11% increase in volume. Notably, this marks the company’s fourth consecutive…
-
Guangxi HSA Expands Coverage for Assisted Reproductive Medical Services Under BMI
•
The Healthcare Security Administration (HSA) bureau of the Guangxi Zhuang Autonomous Region has announced a significant expansion in coverage for assisted reproductive medical services under the Basic Medical Insurance (BMI) and work-related injury insurance fund. This initiative aims to enhance access to essential reproductive health services for residents in the…
-
Siyi Intelligence Secures Approval for Innovative Rehabilitation Robots in China
•
Shanghai-based Siyi Intelligence, a developer of soft rehabilitation robots, has announced that it has received marketing approvals from the National Medical Products Administration (NMPA) for two of its groundbreaking rehabilitation robots: the “Yisheng Upper Limb Intelligent Rehabilitation Training and Evaluation System” and the “Yisheng Brain Computer Interface (BCI) Rehabilitation Training…
-
Triastek Partners with BASF to Advance 3D Printing Materials for Pharmaceuticals
•
China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with German giant BASF SE. This collaboration aims to explore and enhance research and development of new materials for application in drug 3D printing. Financial details of the partnership have not been disclosed. Triastek utilizes a…
-
Novo Nordisk Acquires Global License for Vect-Horus Molecular Cargo Delivery Platform
•
Novo Nordisk (NYSE: NVO), a leading pharmaceutical company based in Denmark, has obtained an exclusive global license to a molecular cargo delivery platform from Vect-Horus, a French specialist in targeted drug delivery. This strategic move is aimed at addressing unmet needs within the treatment of serious chronic diseases. Terms of…
-
Merck KGaA and Jiangsu Hengrui Ink Strategic Collaboration Deal for Next-Gen PARP1 Inhibitor
•
Germany-based Merck KGaA (NYSE: MRK) has announced the signing of a strategic collaboration deal with China’s Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276). This agreement grants Merck development, manufacturing, and commercial rights to the next-generation PARP1 inhibitor HRS-1167 for all global territories outside of China. Additionally, Merck has an option…
-
Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment
•
Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to discuss the recent US FDA approval for Loqtorzi (toripalimab) as both a first- and second-line treatment for nasopharyngeal carcinoma (NPC). This approval, co-developed with Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), marks a…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Pfizer Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
